These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15011576)

  • 1. [A "once daily" drug that with proven effectiveness. Efavirenz has successful outcome also in direct comparisons].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():12-3. PubMed ID: 15011576
    [No Abstract]   [Full Text] [Related]  

  • 2. [Nevirapine has gained acceptance. Good antiretroviral effect--favorable lipid profile].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():76-8. PubMed ID: 15011598
    [No Abstract]   [Full Text] [Related]  

  • 3. Dose-ranging studies.
    Manion D
    Int J Clin Pract Suppl; 1999 Jun; 103():8-9. PubMed ID: 10622036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Positive change from protease inhibitor to non-nucleoside reverse transcriptase inhibitor efavirenz. Improved virus control thanks to protease inhibitor switch].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():37-8. PubMed ID: 11373775
    [No Abstract]   [Full Text] [Related]  

  • 5. 48-week data released for combination treatment with efavirenz.
    AIDS Patient Care STDS; 1999 Jul; 13(7):438-40. PubMed ID: 10870602
    [No Abstract]   [Full Text] [Related]  

  • 6. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efavirenz--comprehensive status of studies].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
    [No Abstract]   [Full Text] [Related]  

  • 8. [Long-term success in routine clinical practice. Effectiveness trial passed].
    MMW Fortschr Med; 2000; 142(3 Suppl):30-1. PubMed ID: 10893961
    [No Abstract]   [Full Text] [Related]  

  • 9. [Progress in HIV therapy. Effective and simple therapy with efavirenz].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():36-7. PubMed ID: 11373774
    [No Abstract]   [Full Text] [Related]  

  • 10. Issues in antiretroviral toxicity.
    Boyle BA
    AIDS Read; 2003 Oct; 13(10):459, 463-4, 468-9, 479. PubMed ID: 14596223
    [No Abstract]   [Full Text] [Related]  

  • 11. New once-daily HIV combination better tolerated.
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):826. PubMed ID: 15566325
    [No Abstract]   [Full Text] [Related]  

  • 12. [CROI highlights of D:A:D Study (Data Collection on Adverse Events of Anti-HIV Drugs Study) and 2NN Study. Stepping into the grease pot].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():83. PubMed ID: 15011604
    [No Abstract]   [Full Text] [Related]  

  • 13. Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
    Winston A; Pozniak A; Smith N; Fletcher C; Mandalia S; Parmar D; Gibbons S; Back D; Gazzard B; Nelson M
    AIDS; 2004 Feb; 18(3):572-4. PubMed ID: 15090815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily drug for persons with HIV.
    Am Fam Physician; 1998 Dec; 58(9):2174-5. PubMed ID: 9861886
    [No Abstract]   [Full Text] [Related]  

  • 16. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
    Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G;
    J Infect Dis; 2005 Mar; 191(6):830-9. PubMed ID: 15717256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin eruption 8 days after a single dose of efavirenz-containing combination therapy.
    Yazaki H; Kikuchi Y; Oka S
    Jpn J Infect Dis; 2001 Dec; 54(6):246-7. PubMed ID: 11862010
    [No Abstract]   [Full Text] [Related]  

  • 18. Warning on two specific 3-drug regimens: Viread + Didanosine + either Sustiva or Viramune.
    AIDS Treat News; 2004 Oct; (406):5. PubMed ID: 15614963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
    Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.